RhumbLine Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-142,603
| Closed | -$434K | – | 4175 |
|
|
2024
Q4 | $434K | Buy |
142,603
+6,885
| +5% | +$30K | ﹤0.01% | 2763 |
|
|
2024
Q3 | $704K | Sell |
135,718
-629
| -0.5% | -$3.13K | ﹤0.01% | 2473 |
|
|
2024
Q2 | $350K | Buy |
136,347
+14,191
| +12% | +$48.5K | ﹤0.01% | 2912 |
|
|
2024
Q1 | $601K | Buy |
122,156
+2,699
| +2% | +$16K | ﹤0.01% | 2548 |
|
|
2023
Q4 | $1.05M | Buy |
119,457
+1,678
| +1% | +$13.7K | ﹤0.01% | 2221 |
|
|
2023
Q3 | $1.35M | Buy |
117,779
+1,753
| +2% | +$33.7K | ﹤0.01% | 2052 |
|
|
2023
Q2 | $2.94M | Buy |
116,026
+9,415
| +9% | +$293K | ﹤0.01% | 1694 |
|
|
2023
Q1 | $3.43M | Buy |
106,611
+3,961
| +4% | +$123K | ﹤0.01% | 1536 |
|
|
2022
Q4 | $1.9M | Buy |
102,650
+10,012
| +11% | +$229K | ﹤0.01% | 1813 |
|
|
2022
Q3 | $2.5M | Buy |
92,638
+9,195
| +11% | +$187K | ﹤0.01% | 1637 |
|
|
2022
Q2 | $1.15M | Buy |
83,443
+2,541
| +3% | +$39.1K | ﹤0.01% | 2068 |
|
|
2022
Q1 | $1.58M | Sell |
80,902
-759
| -0.9% | -$11.5K | ﹤0.01% | 1929 |
|
|
2021
Q4 | $1.33M | Sell |
81,661
-3,815
| -4% | -$63.6K | ﹤0.01% | 2090 |
|
|
2021
Q3 | $2.38M | Buy |
85,476
+3,013
| +4% | +$86K | ﹤0.01% | 1803 |
|
|
2021
Q2 | $2.44M | Sell |
82,463
-5,866
| -7% | -$169K | ﹤0.01% | 1845 |
|
|
2021
Q1 | $2.47M | Sell |
88,329
-7,492
| -8% | -$207K | ﹤0.01% | 1814 |
|
|
2020
Q4 | $2.72M | Buy |
95,821
+8,008
| +9% | +$207K | ﹤0.01% | 1694 |
|
|
2020
Q3 | $2.21M | Sell |
87,813
-14,252
| -14% | -$374K | ﹤0.01% | 1624 |
|
|
2020
Q2 | $2.49M | Buy |
102,065
+20,597
| +25% | +$407K | ﹤0.01% | 1603 |
|
|
2020
Q1 | $1.21M | Buy |
81,468
+13,577
| +20% | +$281K | ﹤0.01% | 1796 |
|
|
2019
Q4 | $1.1M | Buy |
67,891
+1,237
| +2% | +$19.2K | ﹤0.01% | 2035 |
|
|
2019
Q3 | $867K | Buy |
66,654
+3,258
| +5% | +$39.9K | ﹤0.01% | 2109 |
|
|
2019
Q2 | $822K | Buy |
63,396
+14,272
| +29% | +$180K | ﹤0.01% | 2145 |
|
|
2019
Q1 | $774K | Buy |
49,124
+5,785
| +13% | +$100K | ﹤0.01% | 2146 |
|
|
2018
Q4 | $872K | Buy |
43,339
+14,011
| +48% | +$309K | ﹤0.01% | 2076 |
|
|
2018
Q3 | $729K | Sell |
29,328
-2,125
| -7% | -$57.8K | ﹤0.01% | 2130 |
|
|
2018
Q2 | $863K | Buy |
31,453
+7,287
| +30% | +$219K | ﹤0.01% | 2076 |
|
|
2018
Q1 | $744K | Buy |
24,166
+2,890
| +14% | +$93K | ﹤0.01% | 2066 |
|
|
2017
Q4 | $761K | Sell |
21,276
-4,327
| -17% | -$124K | ﹤0.01% | 2068 |
|
|
2017
Q3 | $705K | Buy |
25,603
+270
| +1% | +$6.54K | ﹤0.01% | 2154 |
|
|
2017
Q2 | $669K | Buy |
25,333
+2,395
| +10% | +$53.4K | ﹤0.01% | 2160 |
|
|
2017
Q1 | $477K | Buy |
22,938
+1,952
| +9% | +$40.1K | ﹤0.01% | 2275 |
|
|
2016
Q4 | $434K | Buy |
20,986
+1,556
| +8% | +$26.1K | ﹤0.01% | 2297 |
|
|
2016
Q3 | $315K | Buy |
19,430
+400
| +2% | +$5.81K | ﹤0.01% | 2459 |
|
|
2016
Q2 | $259K | Buy |
19,030
+2,420
| +15% | +$42.8K | ﹤0.01% | 2611 |
|
|
2016
Q1 | $290K | Buy |
16,610
+590
| +4% | +$12K | ﹤0.01% | 2543 |
|
|
2015
Q4 | $547K | Buy |
16,020
+2,170
| +16% | +$75.2K | ﹤0.01% | 2191 |
|
|
2015
Q3 | $412K | Buy |
13,850
+551
| +4% | +$16.7K | ﹤0.01% | 2364 |
|
|
2015
Q2 | $425K | Buy |
+13,299
| New | +$342K | ﹤0.01% | 2437 |
|
|
2014
Q3 | – | Sell |
-6,274
| Closed | -$213K | – | 2990 |
|
|
2014
Q2 | $213K | Buy |
+6,274
| New | +$197K | ﹤0.01% | 2799 |
|
Other funds holding RVNC
RhumbLine Advisers's RVNC Position: Q1 2025 in Review
RhumbLine Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 142,603 shares — an estimated $434K sold.
RhumbLine Advisers first reported a position in RVNC in Q2 2014 and held it in 40 quarters. The position peaked at $3.43M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- RhumbLine Advisers reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- RhumbLine Advisers sold 142,603 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $434K.
- RhumbLine Advisers first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 40 quarters.
- RhumbLine Advisers's Revance Therapeutics, Inc. position peaked at $3.43M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on RhumbLine Advisers's 13F filing for Q1 2025, filed 8 Apr 2025.